5 Fibrinolysis and atherosclerosis

Bailliere's Clinical Haematology

Volumn 8, Issue 2, 1995, Pages 345-363

  Hamsten, Anders ^a   Eriksson, Per ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROSIS; FIBRINOLYSIS; HUMAN; ISCHEMIC HEART DISEASE; METABOLIC DISORDER; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS;

ANIMAL; ARTERIOSCLEROSIS; BASE SEQUENCE; CORONARY DISEASE; FIBRINOLYSIS; HUMAN; MOLECULAR SEQUENCE DATA; RISK FACTORS; SUPPORT, NON-U.S. GOV'T;

EID: 0029075608     PISSN: 09503536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-3536(05)80272-0     Document Type: Article

References (119)

1. Insulin stimulates the synthesis of plasminogen activator inhibitor 1 by hepatocellular cell line Hep G2
2. Increased fibrinolytic potential after diet intervention in healthy coronary high-risk individuals
3. Effects of gemfibrozil on lipids and haemostasis after myocardial infarction
4. Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin
5. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridemic men
6. Weight in infancy and death from ischaemic heart disease
7. Fetal and placental size and risk of hypertension in adult life
8. Type 2 (non insulin dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth
9. The LDL-receptor-related protein, LRP is an apolipoprotein E-binding protein
10. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies
11. 2-macroglobulin receptor is a hepatic receptor for tissue-type plasminogen activator (t-PA)
12. Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease
13. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis
14. Physiological consequences of loss of plasminogen activator gene function in mice
15. Plasminogen activator inhibitor in plasma is related to testosterone in men
16. Fibrinolytic activity and coronary-artery disease
17. Phosphatidylinositol turnover during stimulation of plasminogen activator inhibitor-1 secretion induced by oxidized low density lipoproteins in human endothelial cells
18. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients. A case-control study
19. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity
20. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review
21. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in Hep G2 cells
22. Lipoprotein(a) inhibits streptokinase-mediated activation of human plasminogen
23. Effect of treatment of hyperlipidaemia on haemostatic variables
24. Raised plasma oestriol and oestrone levels in young survivors of myocardial infarction
25. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
26. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis
27. Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1
28. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately over weight adults
29. Fibrinolytic activity in men with acute myocardial infarction before 60 years of age
30. Stimulation of PAI-1 expression in endothelial cells by cultured vascular smooth muscle cells
31. Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein(a) compete for the same site
32. A selective depression of tissue plasminogen activator (t-PA) activity in euglobulins characterises a risk group among survivors of acute myocardial infarction
33. On the usefulness of fibrinolysis variables in the characterization of a risk group for myocardial reinfarction
34. Short term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man
35. Impact of smoking, physical training and weight reduction on FVII, PAI-1 and haemostatic markers in sedentary men
36. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis
37. Fetal and infant growth and impaired glucose tolerance at age 64
38. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
39. Haemostatic function in myocardial infarction
40. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction
41. Plasmin catalyzes binding of lipoprotein(a) to immobilized fibrinogen and fibrin
42. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization
43. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction
44. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control
45. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up
46. Relationships between plasma insulin, triglyceride, body mass index, and plasminogen activator inhibitor 1
47. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis
48. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris
49. Lipoprotein (a) and plasminogen are immunochemically related
50. Serum estrogen levels in men with acute mycordial infarction
51. Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis
52. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes
53. Blood coagulation and fibrinolysis in man after myocardial infarction compared with a representative population sample
54. Low-density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins
55. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1
56. The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man
57. Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinaemic, euglycaemic clamp in man
58. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells
59. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells
60. Sex hormones, insulin, lipid, and prevalent ischemic heart disease
61. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
62. Lipoprotein (a), fibrin binding and plaminogen activation
63. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries
64. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose
65. Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy
66. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen
67. Haemostatic function and cardiovascular death: early results of a prospective study
68. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study
69. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
70. Dietary regulation of fibrinolytic factors
71. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations
72. A potential basis for the thrombotic risks associated with lipoprotein(a)
73. A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction
74. Extracellular matrix degradation
75. Physiological mechanisms for metalloproteinase activation.
76. Hypertriglyceridemia and regulation of fibrinolytic activity
77. The relationships of concentrations of insulin, intact proinsulin and 32–33 split proinsulin with cardiovascular risk factors in type 2 (non insulin dependent) diabetic subjects
78. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis
79. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease
80. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo
81. 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes
82. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease
83. 2-macroglobulin receptor
84. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease
85. Determinants of plasminogen activator inhibitor-1 activity in treated type 2 diabetes and its relation to a polymorphism in the plasminogen activator inhibitor-1 gene
86. Evidence for hyperoestrogenaemia as a risk factor for myocardial infarction in men
87. Relationship between serum sex hormones and glucose, insulin, and lipid abnormalities in men with myocardial infarction
88. Relationship between sex hormones and the glucose-insulin-lipid defect in men with obesity
89. Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort
90. The association of hypotestosteronemia with coronary artery disease in men
91. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance
92. Plasminogen activator inhibitor activity in various types of endogeneous hypertriglyceridemia
93. Fibrinolytic capacity of arm and leg veins after femoral shaft fracture and acute myocardial infarction
94. Influence of plaque configuration and stress distribution of fissuring of coronary atherosclerotic plaques
95. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
96. Augmentation of synthesis of plasminogen activator inhibitor type-1 by insulin and insulin-like growth factor type-1: implications for vascular disease by hyper-insulinemic states
97. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells
98. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
99. Hypertriglyceridaemia and hypercoagulability
100. Role of endothelium in sequestration of lipoprotein and fibrinogen in aortic lesions, thrombi and graft pseudointima
101. Sensitive and specific two site immunoradiometric assays for human insulin, proinsulin, 65–66 split and 32–33 split proinsulins
102. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein
103. The effect of body build, diet and endocrine factors on the extrinsic fibrinolytic system in healthy young women
104. Reduction of elevated plasminogen activator inhibitor levels during modest weight loss
105. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a North Swedish population
106. Insulin deficiency in non insulin dependent diabetes
107. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina
108. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon
109. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non diabetic obese subjects
110. Fat distribution and plasminogen activator inhibitor activity in non-diabetic obese women
111. Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries
112. No evidence for short-term regulation of plasminogen activator inhibitor activity by insulin in man
113. Disordered ‘fibrinolytic potential’ in coronary heart disease
114. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in cultured human vascular smooth muscle cells
115. Impaired fibrinolysis and risk of thromboembolism
116. Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men
117. Genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis
118. Circulating proinsulinlike molecules